292 lines
160 KiB
Text
292 lines
160 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK154652">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK154652/?report=reader">
|
|
<meta name="ncbi_pagename" content="Congenital Erythropoietic Porphyria - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Congenital Erythropoietic Porphyria - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/cda1/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/cftd/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Congenital Erythropoietic Porphyria">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2021/04/15">
|
|
<meta name="citation_author" content="Angelika Erwin">
|
|
<meta name="citation_author" content="Manisha Balwani">
|
|
<meta name="citation_author" content="Robert J Desnick">
|
|
<meta name="citation_author" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network">
|
|
<meta name="citation_pmid" content="24027798">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/">
|
|
<meta name="citation_keywords" content="Günther Disease">
|
|
<meta name="citation_keywords" content="Günther disease">
|
|
<meta name="citation_keywords" content="Erythroid transcription factor">
|
|
<meta name="citation_keywords" content="Uroporphyrinogen-III synthase">
|
|
<meta name="citation_keywords" content="GATA1">
|
|
<meta name="citation_keywords" content="UROS">
|
|
<meta name="citation_keywords" content="Congenital Erythropoietic Porphyria">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Congenital Erythropoietic Porphyria">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Angelika Erwin">
|
|
<meta name="DC.Contributor" content="Manisha Balwani">
|
|
<meta name="DC.Contributor" content="Robert J Desnick">
|
|
<meta name="DC.Contributor" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network">
|
|
<meta name="DC.Date" content="2021/04/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/">
|
|
<meta name="description" content="Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink-to-dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from nonimmune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood.">
|
|
<meta name="og:title" content="Congenital Erythropoietic Porphyria">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink-to-dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from nonimmune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/cep/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK154652/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D065A7C8444510000000000880066.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK154652/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/cda1/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Congenital Erythropoietic Porphyria</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/cftd/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK154652/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK154652/&text=Congenital%20Erythropoietic%20Porphyria"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK154652/?report=classic">Switch to classic view</a><a href="/books/NBK154652/pdf/Bookshelf_NBK154652.pdf">PDF (547K)</a><a href="/books/NBK154652/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK154652%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D065A7C8444510000000000880066.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK154652_"><span class="title" itemprop="name">Congenital Erythropoietic Porphyria</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Günther Disease</div><p class="contribs">Erwin A, Balwani M, Desnick RJ; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network.</p><p class="fm-aai"><a href="#_NBK154652_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 27 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cep.Summary" itemprop="description"><h2 id="_cep_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink-to-dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from nonimmune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CEP in a proband with suggestive clinical and biochemical findings is most commonly established by identification of biallelic pathogenic variants in <i>UROS</i>, and – on rare occasion – by identification of a hemizygous pathogenic variant in the X-linked gene <i>GATA1</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> There is no FDA-approved treatment for CEP or specific treatment for the photosensitivity. Currently, the only effective management is prevention of blistering by avoidance of sun and light exposure, including the long-wave ultraviolet light that passes through window glass or is emitted from artificial light sources. Therefore, the use of protective clothing, wraparound sunglasses, protective window films, reddish incandescent bulbs, filtering screens for fluorescent lights, and opaque sunscreens containing zinc oxide or titanium oxide is recommended. Wound care is necessary to prevent infection of opened blisters; surgical intervention may be necessary; blood transfusions are necessary when hemolysis is significant. Bone marrow transplantation (BMT) is the only cure for CEP and should be considered in children with severe cutaneous and hematologic involvement.</p><p><i>Surveillance:</i> Monitor hematologic indices to assess hemolysis every six months. In those receiving transfusions, monitor for hemolysis more frequently and for iron overload. Monitor hepatic function and vitamin D 25-OH every six to twelve months in all affected individuals.</p><p><i>Agents/circumstances to avoid:</i> All affected individuals: avoid sunlight and UV light. In those with hepatic dysfunction: avoid drugs that may induce cholestasis.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate at-risk sibs as newborns or infants in order to identify as early as possible those who would benefit from early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia.</p><p><i>Pregnancy management:</i> Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to a mother with CEP during delivery.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CEP caused by biallelic <i>UROS</i> pathogenic variants is inherited in an autosomal recessive (AR) manner. CEP caused by a hemizygous <i>GATA1</i> pathogenic variant is inherited in an X-linked (XL) manner.</p><ul><li class="half_rhythm"><div><b>AR CEP.</b> At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic.</div></li><li class="half_rhythm"><div><b>XL CEP.</b> If the mother of an affected male is heterozygous for a <i>GATA1</i> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder phenotype.</div></li><li class="half_rhythm"><div><b>Both AR and XL CEP.</b> Once the pathogenic variant(s) in the family have been identified, carrier testing for at-risk family members, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.</div></li></ul></div></div><div id="cep.Diagnosis"><h2 id="_cep_Diagnosis_">Diagnosis</h2><p>No consensus clinical diagnostic criteria for congenital erythropoietic porphyria (CEP) have been published.</p><div id="cep.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Congenital erythropoietic porphyria (CEP) <b>should be suspected</b> in individuals with the following clinical and laboratory findings and family history.</p><p>
|
|
<b>Clinical findings</b>
|
|
</p><ul><li class="half_rhythm"><div>Nonimmune hydrops fetalis</div></li><li class="half_rhythm"><div>Signs of congenital erythropoietic porphyria</div><ul><li class="half_rhythm"><div>Pink-to-dark red discoloration of the urine (pink or dark red urine-stained diapers are often the first sign in infants)</div></li><li class="half_rhythm"><div>Hemolytic anemia</div></li><li class="half_rhythm"><div>Severe cutaneous photosensitivity with onset usually in infancy or early childhood</div></li><li class="half_rhythm"><div>Blisters and vesicles in light-exposed areas, which are prone to rupture and infection</div></li><li class="half_rhythm"><div>Scarring and deformities (photomutilation) of digits and facial features, caused by recurrent blistering, infections, and bone resorption</div></li><li class="half_rhythm"><div>In light-exposed areas: friable skin, skin thickening, hypo- and hyperpigmentation</div></li><li class="half_rhythm"><div>Reddish-brown discoloration of teeth (fluoresce on exposure to long-wave ultraviolet light), also called erythrodontia</div></li><li class="half_rhythm"><div>Corneal ulcers and scarring</div></li><li class="half_rhythm"><div>Hypertrichosis of the face and extremities</div></li></ul></li></ul><p><b>Laboratory findings</b> include markedly increased levels of uroporphyrin I and coproporphyrin I isomers in erythrocytes, urine, or amniotic fluid as well as coproporphyrin I in stool (see <a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepTbiochemicalcharacteristicsofcon"><a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figobcepTbiochemicalcharacteristicsofcon"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.T.biochemical_characteristics_of_con"><a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1. </a></h4><p class="float-caption no_bottom_margin">Biochemical Characteristics of Congenital Erythropoietic Porphyria </p></div></div><p><b>Family history</b> is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity) or, rarely, X-linked inheritance (e.g., no male-to-male transmission). Absence of a known family history does not preclude the diagnosis.</p></div><div id="cep.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CEP <b>is established</b> by biochemical testing, which shows marked elevation of the uroporphyrin and coproporphyrin I isomers (see <a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>), and should be confirmed by molecular genetic testing for biallelic <i>UROS</i> pathogenic variants. On rare occasion, a hemizygous pathogenic variant in the X-linked gene <i>GATA1</i> can be identified [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>] (see <a href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-ob="figobcepTmoleculargenetictestingusedin">Table 2</a>).</p><p>Note:</p><ul><li class="half_rhythm"><div>In the absence of biochemical or enzymatic testing results, identification of biallelic <i>UROS</i> variants of uncertain significance (or identification of one known <i>UROS</i> pathogenic variant and one <i>UROS</i> variant of uncertain significance) does not establish or rule out a diagnosis autosomal recessive CEP.</div></li><li class="half_rhythm"><div>If the diagnosis cannot be established by molecular genetic testing, the findings of reduced URO-synthase activity in erythrocytes and markedly elevated urinary or erythrocyte uroporphyrin and coproporphyrin I isomers (<a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>) confirm the diagnosis and indicate that the variants of uncertain significance may be pathogenic.</div></li><li class="half_rhythm"><div>Identification of a hemizygous <i>GATA1</i> variant of uncertain significance does not establish or rule out a diagnosis of X-linked CEP.</div></li></ul><p>Molecular genetic testing approaches can include <b>gene-targeted testing</b> (single gene or multigene panel) or <b>comprehensive</b>
|
|
<b>genomic testing</b> (exome sequencing, genome sequencing).</p><p>Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in <a href="#cep.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#cep.Option_1">Option 1</a>), whereas those in whom the diagnosis of CEP has not been considered are more likely to be diagnosed using genomic testing (see <a href="#cep.Option_2">Option 2</a>).</p><div id="cep.Option_1"><h4>Option 1</h4><p><b>A multigene panel</b> such as a comprehensive porphyrias panel that includes <i>UROS</i>, <i>GATA1</i>, and other genes of interest (see <a href="#cep.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="cep.Option_2"><h4>Option 2</h4><p><b>Comprehensive</b>
|
|
<b>genomic testing</b> does not require the clinician to determine which gene is likely involved. <b>Exome sequencing</b> is most commonly used; <b>genome sequencing</b> is also possible.</p><p>For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepTmoleculargenetictestingusedin"><a href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figobcepTmoleculargenetictestingusedin"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.T.molecular_genetic_testing_used_in"><a href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-ob="figobcepTmoleculargenetictestingusedin">Table 2. </a></h4><p class="float-caption no_bottom_margin">Molecular Genetic Testing Used in Congenital Erythropoietic Porphyria </p></div></div></div></div></div><div id="cep.Clinical_Characteristics"><h2 id="_cep_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cep.Clinical_Description"><h3>Clinical Description</h3><p>Most individuals with congenital erythropoietic porphyria (CEP) experience severe cutaneous photosensitivity in early infancy; the first manifestation is often pink-to-dark red discoloration of the urine. Hemolytic anemia is common and can be mild to severe, requiring chronic erythrocyte transfusions in some. The phenotypic spectrum ranges from severe (nonimmune hydrops fetalis) to milder disease (adult-onset with isolated cutaneous manifestations) [<a class="bibr" href="#cep.REF.warner.1992.693" rid="cep.REF.warner.1992.693">Warner et al 1992</a>]. (See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> for variants that correlate with disease severity.)</p><p><b>Skin.</b> Cutaneous photosensitivity is present at birth or in early infancy and is characterized by blistering and increased friability of the skin over light-exposed areas. Bullae and vesicles are filled with serous fluid and are prone to rupture. Secondary infections with scarring and bone resorption (photomutilation) may lead to deformity and disfigurement of fingers, toes, and facial features including the nose, ears, and eyelids. Skin thickening, focal hyper- or hypopigmentation, and hypertrichosis of face and extremities may occur [<a class="bibr" href="#cep.REF.pohfitzpatrick.1986.291" rid="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</a>].</p><p>Photosensitivity symptoms are provoked mainly by visible light (400-410 nm Soret wavelength) and to a lesser degree by wavelengths in the long-wave UV region. Affected individuals are also sensitive to sunlight that passes through window glass that does not filter long-wave UVA or visible light as well as to light from artificial light sources.</p><p>Unlike the cutaneous manifestations in <a href="/books/n/gene/epp-ar/?report=reader">erythropoietic protoporphyria</a> (EPP), manifestations such as tingling, burning, itching, or swelling usually do not occur in persons with CEP after light exposure.</p><p><b>Hemolytic anemia.</b> Mild-to-severe hemolytic anemia with anisocytosis, poikilocytosis, polychromasia, basophilic stippling, and reticulocytosis is common in CEP. Findings also include the absence of haptoglobin, increased unconjugated bilirubin, and increased fecal urobilinogen [<a class="bibr" href="#cep.REF.schmid.1955.416" rid="cep.REF.schmid.1955.416">Schmid et al 1955</a>]. Hemolysis presumably results from the accumulation of uroporphyrinogen I in the erythrocytes [<a class="bibr" href="#cep.REF.bishop.2006.645" rid="cep.REF.bishop.2006.645">Bishop et al 2006</a>].</p><p>Those with severe hemolytic anemia often require chronic erythrocyte transfusions, which decrease porphyrin production by suppressing erythropoiesis, but can lead to iron overload and other complications [<a class="bibr" href="#cep.REF.piomelli.1986.1029" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>].</p><p>Secondary splenomegaly may develop as a consequence of hemolytic anemia. In addition to worsening the anemia, it can also result in leukopenia and thrombocytopenia, which may be associated with significant bleeding [<a class="bibr" href="#cep.REF.pain.1975.621" rid="cep.REF.pain.1975.621">Pain et al 1975</a>, <a class="bibr" href="#cep.REF.weston.1978.921" rid="cep.REF.weston.1978.921">Weston et al 1978</a>, <a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>].</p><p><b>Ophthalmologic involvement.</b> Deposition of porphyrins may lead to corneal ulcers and scarring, which can ultimately lead to blindness. Other ocular manifestations can include scleral necrosis, necrotizing scleritis, seborrheic blepharitis, keratoconjunctivitis, sclerokeratitis, and ectropion [<a class="bibr" href="#cep.REF.oguz.1993.671" rid="cep.REF.oguz.1993.671">Oguz et al 1993</a>, <a class="bibr" href="#cep.REF.venkatesh.2000.314" rid="cep.REF.venkatesh.2000.314">Venkatesh et al 2000</a>, <a class="bibr" href="#cep.REF.siddique.2011.97" rid="cep.REF.siddique.2011.97">Siddique et al 2011</a>].</p><p><b>Erythrodontia.</b> Porphyrin deposition in the teeth produces a reddish-brown color, termed erythrodontia. The teeth may fluoresce on exposure to long-wave ultraviolet light.</p><p><b>Bone involvement.</b> Deposition of porphyrins in bone causes bone loss (osteopenia on x-ray) due to demineralization [<a class="bibr" href="#cep.REF.piomelli.1986.1029" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>, <a class="bibr" href="#cep.REF.laorr.1994.307" rid="cep.REF.laorr.1994.307">Laorr & Greenspan 1994</a>, <a class="bibr" href="#cep.REF.fritsch.1997.594" rid="cep.REF.fritsch.1997.594">Fritsch et al 1997</a>, <a class="bibr" href="#cep.REF.kontos.2003.160" rid="cep.REF.kontos.2003.160">Kontos et al 2003</a>]. It can also cause expansion of the bone marrow, which can lead to hyperplastic bone marrow observed on biopsy [<a class="bibr" href="#cep.REF.pohfitzpatrick.1986.291" rid="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</a>, <a class="bibr" href="#cep.REF.anderson.2001" rid="cep.REF.anderson.2001">Anderson et al 2001</a>].</p><p><b>Vitamin D deficiency.</b> Individuals with CEP who avoid sunlight are at risk for vitamin D deficiency.</p></div><div id="cep.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The genotype-phenotype correlations that have been established in CEP are largely determined by the amount of residual enzyme activity encoded by the specific pathogenic variants (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">Table 5</a>).</p><p><b><i>UROS</i>.</b> The most common <i>UROS</i> pathogenic variant, <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.217T>C</a> (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">p.Cys73Arg</a>), is observed in about one third of individuals with CEP.</p><ul><li class="half_rhythm"><div>Homozygosity for the c.217T>C (p.Cys73Arg) variant results in less than 1% of normal URO-synthase activity and a severe phenotype that may manifest as nonimmune hydrops fetalis [<a class="bibr" href="#cep.REF.frank.1998.225" rid="cep.REF.frank.1998.225">Frank et al 1998</a>, <a class="bibr" href="#cep.REF.desnick.2002.779" rid="cep.REF.desnick.2002.779">Desnick & Astrin 2002</a>].</div></li><li class="half_rhythm"><div>Compound heterozygosity for the c.217T>C (p.Cys73Arg) variant and a pathogenic variant that expresses a very low level of residual activity results in a severe or moderately severe phenotype.</div></li></ul><p>In contrast, individuals with pathogenic variants expressing higher residual activities such as <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.244G>T</a> (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">p.Val82Phe</a>) (35% of normal activity in vitro), <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.311C>T</a> (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">p.Ala104Val</a>) (7.7% of normal activity in vitro), and <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.197C>T</a> (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">p.Ala66Val</a>) (14.5% of normal activity in vitro) have milder phenotypes even if heteroallelic for c.217T>C (p.Cys73Arg) or another pathogenic variant with very low or almost absent residual enzyme activity [<a class="bibr" href="#cep.REF.desnick.2002.779" rid="cep.REF.desnick.2002.779">Desnick & Astrin 2002</a>].</p><p>Determination of genotype-phenotype correlations for erythroid-specific promoter pathogenic variants showed the following:</p><ul><li class="half_rhythm"><div>Compound heterozygotes with the <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.-203T>C</a> variant (2.9% of normal activity in vitro) in combination with the c.217T>C (p.Cys73Arg)table4 variant led to nonimmune hydrops fetalis [<a class="bibr" href="#cep.REF.solis.2001.753" rid="cep.REF.solis.2001.753">Solis et al 2001</a>].</div></li><li class="half_rhythm"><div>The <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.-223C>A</a> variant (8.3% of normal activity in vitro) when in compound heterozygosity with another variant with low residual enzyme activity (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.673G>A [p.Gly225Ser</a>]), 1.2% of normal activity in vitro) led to a moderately severe phenotype in one individual [<a class="bibr" href="#cep.REF.solis.2001.753" rid="cep.REF.solis.2001.753">Solis et al 2001</a>].</div></li><li class="half_rhythm"><div>The two other known erythrocyte-specific promoter pathogenic variants, <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.-209G>A</a> and <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.-219C>A</a>, with high residual activities (53.9% and 43.4% of normal in vitro, respectively) in individuals in whom the second variant was c.217T>C (p.Cys73Arg), led to mild cutaneous disease [<a class="bibr" href="#cep.REF.desnick.2002.779" rid="cep.REF.desnick.2002.779">Desnick & Astrin 2002</a>].</div></li></ul><p><b><i>GATA1</i>.</b> The <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.646C>T</a> (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">p.Arg216Trp</a>) pathogenic variant is predicted to dramatically alter the binding of GATA1 to URO-synthase, resulting in significantly reduced (~20% of normal) URO-synthase activity [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>].</p></div><div id="cep.Nomenclature"><h3>Nomenclature</h3><p>Obsolete terms for CEP are erythropoietic porphyria, congenital porphyria, congenital hematoporphyria, and erythropoietic uroporphyria.</p></div><div id="cep.Prevalence"><h3>Prevalence</h3><p>CEP is an ultra-rare disorder. To date, about 220 affected individuals have been reported.</p></div></div><div id="cep.Genetically_Related_Allelic_Disorder"><h2 id="_cep_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b><i>UROS</i>.</b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>UROS</i>.</p><p><b><i>GATA1.</i></b> Pathogenic variants in this gene are also observed in:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/gata1/?report=reader"><i>GATA1</i>-related X-linked cytopenia</a>;</div></li><li class="half_rhythm"><div><a href="/books/n/gene/diamond-b/?report=reader">Diamond-Blackfan anemia</a>.</div></li></ul></div><div id="cep.Differential_Diagnosis"><h2 id="_cep_Differential_Diagnosis_">Differential Diagnosis</h2><p>See <a href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object" rid-ob="figobcepTdisorderstoconsiderinthediffe">Table 3</a> for other disorders that present with a congenital erythropoietic porphyria (CEP)-like phenotype.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepTdisorderstoconsiderinthediffe"><a href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figobcepTdisorderstoconsiderinthediffe"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.T.disorders_to_consider_in_the_diffe"><a href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object" rid-ob="figobcepTdisorderstoconsiderinthediffe">Table 3. </a></h4><p class="float-caption no_bottom_margin">Disorders to Consider in the Differential Diagnosis of Congenital Erythropoietic Porphyria </p></div></div></div><div id="cep.Management"><h2 id="_cep_Management_">Management</h2><p>A management algorithm for congenital erythropoietic porphyria (CEP) has been published [<a class="bibr" href="#cep.REF.katugampola.2012a.888" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>].</p><div id="cep.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with congenital erythropoietic porphyria (CEP), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Hematologic indices including reticulocytes and bilirubin (to assess hemolysis) and iron profile (to assess iron storage)</div></li><li class="half_rhythm"><div>Serum calcium and vitamin D concentrations; bone densitometry</div></li><li class="half_rhythm"><div>Hepatic function tests, especially in transfusion-dependent individuals given the risk for liver disease due to iron storage</div></li><li class="half_rhythm"><div>Dermatologic evaluation to assess photosensitivity, photomutilation, and secondary skin changes (thickening, hyper- or hypopigmentation, hypertrichosis)</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation for corneal ulcers and scarring and other ocular manifestations</div></li><li class="half_rhythm"><div>Dental assessment for erythrodontia (reddish-brown color from porphyrin deposition)</div></li><li class="half_rhythm"><div>Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of CEP in order to facilitate medical and personal decision making</div></li></ul></div><div id="cep.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Cutaneous photosensitivity.</b> There is no FDA-approved treatment for this disease or specific treatment for the photosensitivity.</p><p>Currently the only effective treatment is prevention of blistering by avoidance of light exposure, including the long-wave ultraviolet sunlight that passes through window glass or light emitted by fluorescent sources:</p><ul><li class="half_rhythm"><div>Sun protection using protective clothing including long sleeves, gloves, and wide-brimmed hats</div></li><li class="half_rhythm"><div>Protective window films for cars and windows at home as well as at school/work to prevent exposure to UV light</div></li><li class="half_rhythm"><div>Replacement of LED and fluorescent lights with reddish incandescent bulbs or installation of filtering screens</div></li><li class="half_rhythm"><div>Reflectant sunscreens containing zinc oxide or titanium dioxide. Note, however, that these may be cosmetically unacceptable and, in any case, do not replace strict avoidance of sun/light exposure.</div></li></ul><p>Skin trauma should be avoided.</p><p>Wound care is essential to prevent infection of opened blisters. Antiseptic and topical/oral antibiotic treatment may be indicated to avoid progression to osteomyelitis and bone resorption with subsequent mutilation.</p><p>Surgical intervention may be indicated for severe mutilation (repair of microstomia, correction of ectropion, reconstruction of the nose).</p><p>Laser hair removal can be used to treat facial hypertrichosis.</p><p>Vitamin D supplementation is advised as affected individuals are predisposed to vitamin D insufficiency due to sun avoidance.</p><p>Immunization for hepatitis A and B is recommended.</p><p>Note: (1) Beta-carotene has been tried in some individuals but without significant benefit. (2) Phototherapy with narrowband ultraviolet B radiation did not show any benefit.</p><p>
|
|
<b>Ocular manifestations</b>
|
|
</p><ul><li class="half_rhythm"><div>Avoidance of damage to the eyelids and cornea by wearing wraparound sunglasses</div></li><li class="half_rhythm"><div>Topical antibiotics for corneal ulcers, scleritis, and blepharitis</div></li><li class="half_rhythm"><div>Artificial tears and lubricants to help prevent dry eyes in those with ectropion</div></li><li class="half_rhythm"><div>Corrective surgery of eyelids to help protect the cornea from injury in those with ectropion [<a class="bibr" href="#cep.REF.katugampola.2012a.888" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>]</div></li></ul><p><b>Bone manifestations.</b> Bisphosphonates can be considered in individuals with osteoporosis [<a class="bibr" href="#cep.REF.katugampola.2012a.888" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>].</p><p>
|
|
<b>Hemolytic anemia</b>
|
|
</p><ul><li class="half_rhythm"><div>Consider frozen matched-erythrocyte transfusions when hemolysis is significant, or bone marrow transplantation</div></li><li class="half_rhythm"><div>Chronic transfusions (every 2-4 weeks) with a target hematocrit greater than 35% can suppress erythropoiesis and decrease porphyrin production, which reduces porphyrin levels and photosensitivity [<a class="bibr" href="#cep.REF.piomelli.1986.1029" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>].</div></li><li class="half_rhythm"><div>Note: In those who receive frequent transfusions, the body iron burden can be reduced with parenteral or oral chelators [<a class="bibr" href="#cep.REF.pohfitzpatrick.1988" rid="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</a>].</div></li><li class="half_rhythm"><div>Experimental induction of iron deficiency either using treatment with iron chelators or via phlebotomies improved photosensitivity and hemolysis in a few affected individuals [<a class="bibr" href="#cep.REF.egan.2015.257" rid="cep.REF.egan.2015.257">Egan at al 2015</a>, <a class="bibr" href="#cep.REF.blouin.2020.2457" rid="cep.REF.blouin.2020.2457">Blouin et al 2020</a>, <a class="bibr" href="#cep.REF.blouin.2021.100722" rid="cep.REF.blouin.2021.100722">Blouin et al 2021</a>, <a class="bibr" href="#cep.REF.mirmiran.2021.913" rid="cep.REF.mirmiran.2021.913">Mirmiran et al 2021</a>].</div></li></ul><p>Note: Although oral charcoal and cholestyramine were thought to increase fecal loss of porphyrins, a clear clinical benefit has not been shown [<a class="bibr" href="#cep.REF.tishler.1990.645" rid="cep.REF.tishler.1990.645">Tishler & Winston 1990</a>].</p><p><b>Successful bone marrow transplantation (BMT)</b> is an effective cure for CEP and should be considered in children with severe cutaneous and hematologic involvement. Autologous as well as allogeneic stem cell transplants have been performed successfully [<a class="bibr" href="#cep.REF.thomas.1996.453" rid="cep.REF.thomas.1996.453">Thomas et al 1996</a>, <a class="bibr" href="#cep.REF.tezcan.1998.4053" rid="cep.REF.tezcan.1998.4053">Tezcan et al 1998</a>, <a class="bibr" href="#cep.REF.harada.2001.279" rid="cep.REF.harada.2001.279">Harada et al 2001</a>, <a class="bibr" href="#cep.REF.shaw.2001.101" rid="cep.REF.shaw.2001.101">Shaw et al 2001</a>, <a class="bibr" href="#cep.REF.dupuisgirod.2005.104" rid="cep.REF.dupuisgirod.2005.104">Dupuis-Girod et al 2005</a>, <a class="bibr" href="#cep.REF.taibjee.2007.567" rid="cep.REF.taibjee.2007.567">Taibjee et al 2007</a>, <a class="bibr" href="#cep.REF.faraci.2008.117" rid="cep.REF.faraci.2008.117">Faraci et al 2008</a>]. Urine and erythrocyte porphyrins can be measured periodically after bone marrow transplantation to monitor engraftment.</p><p>The age of children with CEP receiving BMT ranges from younger than one year to 13 years [<a class="bibr" href="#cep.REF.katugampola.2012b.901" rid="cep.REF.katugampola.2012b.901">Katugampola et al 2012b</a>]. Some of the first individuals with CEP to successfully undergo BMT in childhood are now in their 20s [<a class="bibr" href="#cep.REF.thomas.1996.453" rid="cep.REF.thomas.1996.453">Thomas et al 1996</a>, <a class="bibr" href="#cep.REF.zixkieffer.1996.217" rid="cep.REF.zixkieffer.1996.217">Zix-Kieffer et al 1996</a>]. Although there is limited information available regarding their long-term outcome post BMT, experts have learned that individuals successfully transplanted have essentially no photosensitivity to artificial light sources or sunlight.</p></div><div id="cep.Surveillance"><h3>Surveillance</h3><p>Monitor the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Hematologic indices including iron profile, reticulocyte count, and bilirubin to assess hemolysis every six months</div><div class="half_rhythm">Note: Individuals receiving transfusion therapy need closer monitoring.</div></li><li class="half_rhythm"><div class="half_rhythm">Iron profile on a regular basis to assess for iron overload for those who are transfusion dependent</div></li><li class="half_rhythm"><div class="half_rhythm">Hepatic function every six to twelve months</div></li><li class="half_rhythm"><div class="half_rhythm">Vitamin D 25-OH levels in all individuals whether or not they are receiving vitamin D supplements</div></li></ul></div><div id="cep.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Avoidance of sunlight and UV light</div></li><li class="half_rhythm"><div>In individuals with hepatic dysfunction, avoidance of drugs that may induce cholestasis (e.g., estrogens)</div></li><li class="half_rhythm"><div>In individuals undergoing surgeries, use of protective filters for artificial lights in the operating room to prevent phototoxic damage [<a class="bibr" href="#cep.REF.wahlin.2008.1340" rid="cep.REF.wahlin.2008.1340">Wahlin et al 2008</a>]</div></li></ul></div><div id="cep.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk sibs as newborns or infants in order to identify as early as possible those who would benefit from early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia. Evaluations include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variant(s) in the family are known;</div></li><li class="half_rhythm"><div>Biochemical testing for urinary or erythrocyte uroporphyrin I and coproporphyrin I isomer elevation if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#cep.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="cep.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Successful pregnancies in women with CEP resulting in healthy and unaffected children have been described [<a class="bibr" href="#cep.REF.hallai.2007.622" rid="cep.REF.hallai.2007.622">Hallai et al 2007</a>, <a class="bibr" href="#cep.REF.katugampola.2012b.901" rid="cep.REF.katugampola.2012b.901">Katugampola et al 2012b</a>].</p><p>Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to the mother during delivery [<a class="bibr" href="#cep.REF.wahlin.2008.1340" rid="cep.REF.wahlin.2008.1340">Wahlin et al 2008</a>].</p></div><div id="cep.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Although there are no clinical trials at the present time, therapeutic approaches under investigation include phlebotomy or iron chelation strategies to reduce the hemolysis and decrease the accumulated porphyrins and, thus, photosensitivity [<a class="bibr" href="#cep.REF.egan.2015.257" rid="cep.REF.egan.2015.257">Egan at al 2015</a>, <a class="bibr" href="#cep.REF.blouin.2020.2457" rid="cep.REF.blouin.2020.2457">Blouin et al 2020</a>, <a class="bibr" href="#cep.REF.blouin.2021.100722" rid="cep.REF.blouin.2021.100722">Blouin et al 2021</a>, <a class="bibr" href="#cep.REF.mirmiran.2021.913" rid="cep.REF.mirmiran.2021.913">Mirmiran et al 2021</a>].</p><p>A murine CEP model is being used to investigate pharmacologic chaperone therapy (i.e., administration of small-molecule drugs to enhance the residual activity of mutated enzymes that have low activities or are unstable). Specifically, use of the antimicrobial agent ciclopirox as a chaperone-stabilized UROIII-synthase and reversed CEP-related findings such as abnormal URO I levels in the blood, splenomegaly, and liver porphyrins [<a class="bibr" href="#cep.REF.urquiza.2018.eaat7467" rid="cep.REF.urquiza.2018.eaat7467">Urquiza et al 2018</a>]. Studies involving use of this medication in humans have not yet been performed.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="cep.Genetic_Counseling"><h2 id="_cep_Genetic_Counseling_">Genetic Counseling</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="cep.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Congenital erythropoietic porphyria (CEP) caused by biallelic <i>UROS</i> pathogenic variants is inherited in an autosomal recessive manner.</p><p>CEP caused by a hemizygous <i>GATA1</i> pathogenic variant is inherited in an X-linked manner. To date only three such individuals have been identified [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bibr" href="#cep.REF.di_pierro.2015.491" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p></div><div id="cep.Autosomal_Recessive_Inheritance__Ris"><h3>Autosomal Recessive Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The parents of an affected individual are obligate heterozygotes (i.e., presumed to be carriers of one <i>UROS</i> pathogenic variant based on family history).</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a proband to confirm that both parents are heterozygous for a <i>UROS</i> pathogenic variant and to allow reliable recurrence risk assessment. If a pathogenic variant is detected in only one parent, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>One of the pathogenic variants identified in the proband occurred as a <i>de novo</i> event in the proband.</div></li><li class="half_rhythm"><div>Uniparental isodisomy for the parental chromosome with the pathogenic variant resulted in homozygosity for the pathogenic variant in the proband.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p>
|
|
<b>Sibs of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>If both parents are known to be heterozygous for a <i>UROS</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a proband.</b> Unless an individual with congenital erythropoietic porphyria has children with an affected individual or a carrier, the offspring of a proband will be obligate heterozygotes (carriers) for a pathogenic variant in <i>UROS</i>.</p><p><b>Other family members.</b> Each sib of the proband's parents is at a 50% risk of being a carrier of a <i>UROS</i> pathogenic variant.</p><div id="cep.Carrier_Detection"><h4>Carrier Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the <i>UROS</i> pathogenic variants in the family.</p></div></div><div id="cep.XLinked_Inheritance__Risk_to_Family"><h3>X-Linked Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a male proband</b>
|
|
</p><ul><li class="half_rhythm"><div class="half_rhythm">The father of an affected male will not have the disorder nor will he be hemizygous for the <i>GATA1</i> pathogenic variant; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div class="half_rhythm">In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote. Note: If a woman has more than one affected child and no other affected relatives and if the <i>GATA1</i> pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline mosaicism.</div></li><li class="half_rhythm"><div class="half_rhythm">If a male is the only affected family member (i.e., a simplex case), the mother may be a carrier, the affected male may have a <i>de novo</i>
|
|
<i>GATA1</i> pathogenic variant (in which case the mother is not a carrier), or the mother may have somatic/germline mosaicism.</div><div class="half_rhythm">The frequency of <i>de novo</i>
|
|
<i>GATA1</i> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div class="half_rhythm">Molecular genetic testing of the mother is recommended to confirm her genetic status and to allow reliable recurrence risk assessment.</div></li></ul><p><b>Sibs of a male proband.</b> The risk to sibs of a male proband depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the proband has a <i>GATA1</i> pathogenic variant, the chance of transmitting it in each pregnancy is 50%.</div><ul><li class="half_rhythm"><div>Males who inherit the pathogenic variant will be affected;</div></li><li class="half_rhythm"><div>Females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder phenotype with predominantly hematologic and/or cutaneous abnormalities due to skewed X-chromosome inactivation [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bibr" href="#cep.REF.di_pierro.2015.491" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</div></li></ul></li><li class="half_rhythm"><div>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the <i>GATA1</i> pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is presumed to be low but slightly greater than that of the general population because of the theoretic possibility of maternal germline mosaicism.</div></li></ul><p><b>Offspring of a male proband.</b> Affected males transmit the <i>GATA1</i> pathogenic variant to all of their daughters and none of their sons.</p><p><b>Other family members.</b> The proband's maternal aunts may be at risk of being carriers and the aunts' offspring, depending on their sex, may be at risk of being carriers or of being affected.</p><p>Note: Molecular genetic testing may be able to identify the family member in whom a <i>de novo</i> pathogenic variant arose, information that could help determine genetic risk status of the extended family.</p><div id="cep.Heterozygote_Detection"><h4>Heterozygote Detection</h4><p>Identification of female heterozygotes requires either prior identification of the <i>GATA1</i> pathogenic variant in the family or, if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and if no pathogenic variant is identified, by gene-targeted deletion/duplication analysis.</p><p>Note: Females who are heterozygous for this X-linked disorder will be either asymptomatic or have a milder phenotype with predominantly hematologic abnormalities due to skewed X-chromosome inactivation [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bibr" href="#cep.REF.di_pierro.2015.491" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p></div></div><div id="cep.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#cep.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>
|
|
<b>Family planning</b>
|
|
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown).</p></div><div id="cep.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p><b>Molecular genetic testing.</b> Once the <i>UROS</i> pathogenic variants or the <i>GATA1</i> pathogenic variant have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.</p><p><b>Biochemical genetic testing.</b> Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells, and/or markedly elevated uroporphyrin I and coproporphyrin I concentrations in amniotic fluid (see <a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>).</p><p>Note: It is assumed that an elevation of uroporphyrin I and coproporphyrin I concentrations in amniotic fluid is also present in <i>GATA1</i>-related CEP; however, at this time data are insufficient to confirm this hypothesis.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.</p></div></div><div id="cep.Resources"><h2 id="_cep_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>American Porphyria Foundation (APF)</b>
|
|
</div><div><b>Phone:</b> 866-APF-3635</div><div><b>Email:</b> general@porphyriafoundation.org</div><div>
|
|
<a href="https://www.porphyriafoundation.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.porphyriafoundation.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>MedlinePlus</b>
|
|
</div><div>
|
|
<a href="https://medlineplus.gov/genetics/condition/porphyria/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Porphyria</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>United Porphyrias Association</b>
|
|
</div><div><b>Phone:</b> 800-868-1292</div><div><b>Email:</b> info@porphyria.org</div><div>
|
|
<a href="https://www.porphyria.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.porphyria.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b>
|
|
</div><div>Canada</div><div>
|
|
<a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.canadianassociationforporphyria.ca</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Find a Porphyria Expert</b>
|
|
</div><div>American Porphyria Foundation</div><div>
|
|
<a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Global Porphyria Advocacy Coalition</b>
|
|
</div><div>
|
|
<a href="https://www.gpac-porphyria.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">GPAC</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>International Porphyria Network</b>
|
|
</div><div><b>Email:</b> contact@porphyria.eu</div><div>
|
|
<a href="http://porphyria.eu/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">porphyria.eu</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Porphyria South Africa</b>
|
|
</div><div>South Africa</div><div><b>Phone:</b> +27 21-4066332</div><div><b>Fax:</b> +27 21-4066061</div><div><b>Email:</b> Peter.Meissner@uct.ac.za</div><div>
|
|
<a href="http://www.porphyria-patients.uct.ac.za/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Porphyria for Patients</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Swedish Porphyria Association</b>
|
|
</div><div>Sweden</div><div><b>Phone:</b> +46730803820</div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div>
|
|
<a href="http://www.porfyri.se" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.porfyri.se</a>
|
|
</div></li></ul>
|
|
</div><div id="cep.Molecular_Genetics"><h2 id="_cep_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepmolgenTA"><a href="/books/NBK154652/table/cep.molgen.TA/?report=objectonly" target="object" title="Table A." class="img_link icnblk_img" rid-ob="figobcepmolgenTA"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.molgen.TA"><a href="/books/NBK154652/table/cep.molgen.TA/?report=objectonly" target="object" rid-ob="figobcepmolgenTA">Table A.</a></h4><p class="float-caption no_bottom_margin">Congenital Erythropoietic Porphyria: Genes and Databases </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepmolgenTB"><a href="/books/NBK154652/table/cep.molgen.TB/?report=objectonly" target="object" title="Table B." class="img_link icnblk_img" rid-ob="figobcepmolgenTB"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.molgen.TB"><a href="/books/NBK154652/table/cep.molgen.TB/?report=objectonly" target="object" rid-ob="figobcepmolgenTB">Table B.</a></h4><p class="float-caption no_bottom_margin">OMIM Entries for Congenital Erythropoietic Porphyria (View All in OMIM) </p></div></div><div id="cep.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>CEP results from markedly decreased (but not absent) URO-synthase activity (<1% to ~10% of normal). When expressed in vitro, the residual enzyme activity of individual pathogenic variants ranges from less than 1.0% to approximately 35% [<a class="bibr" href="#cep.REF.desnick.2002.779" rid="cep.REF.desnick.2002.779">Desnick & Astrin 2002</a>].</p><p>URO-synthase, the fourth enzyme in the heme biosynthesis pathway, normally converts hydroxymethylbilane (HMB) to uroporphyrinogen III. When URO-synthase activity is deficient, HMB accumulates primarily in the erythron and is non-enzymatically converted to uroporphyrinogen I. Decarboxylation of uroporphyrinogen I by URO-decarboxylase leads to formation of hepta-, hexa-, and pentacarboxyl porphyrinogen I isomers, with coproporphyrinogen I being the final product. Since coproporphyrinogen oxidase is specific for the III isomer, coproporphyrinogen I cannot be further metabolized to heme and is therefore non-physiologic. Isomer I porphyrinogens are pathogenic when they accumulate in large amounts and are auto-oxidized to their corresponding porphyrins [<a class="bibr" href="#cep.REF.piomelli.1986.1029" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>, <a class="bibr" href="#cep.REF.pohfitzpatrick.1988" rid="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</a>].</p><p>Porphyrinogen I isomers accumulate in bone marrow erythroid precursors; erythrocytes undergo auto-oxidation, which causes damage of the erythrocytes and hemolysis. Porphyrin I isomers are released into the circulation and deposited in skin, bone, and other tissues as well as excreted in urine and feces [<a class="bibr" href="#cep.REF.desnick.1998.77" rid="cep.REF.desnick.1998.77">Desnick et al 1998</a>].</p><p>Urinary porphyrin excretion is markedly increased (100-1,000x normal) and consists mainly of uroporphyrin I and coproporphyrin I, with lesser increases in hepta-, hexa-, and pentacarboxyl porphyrin isomers [<a class="bibr" href="#cep.REF.fritsch.1997.594" rid="cep.REF.fritsch.1997.594">Fritsch et al 1997</a>]. While isomer I porphyrins are predominant, isomer III porphyrins are also increased.</p><p>Cutaneous photosensitivity with blistering and increased friability occurs because the porphyrins deposited in the skin are photocatalytic and cytotoxic compounds [<a class="bibr" href="#cep.REF.pohfitzpatrick.1985" rid="cep.REF.pohfitzpatrick.1985">Poh-Fitzpatrick 1985</a>]. Presumably, exposure of the skin to sunlight or other sources of visible light in the Soret band (400-410 nm) and to a lesser extent long-wave ultraviolet light leads to a phototoxic excitation of the accumulated uroporphyrin I and coproporphyrin I isomers. This results in formation of singlet oxygen and other oxygen radicals, which presumably produce tissue and vessel damage [<a class="bibr" href="#cep.REF.kaufman.1967.210" rid="cep.REF.kaufman.1967.210">Kaufman et al 1967</a>, <a class="bibr" href="#cep.REF.bickers.1987.261" rid="cep.REF.bickers.1987.261">Bickers 1987</a>, <a class="bibr" href="#cep.REF.dawe.2002.680" rid="cep.REF.dawe.2002.680">Dawe et al 2002</a>].</p><p>The bone marrow contains much larger amounts of porphyrins (mostly uroporphyrin I and coproporphyrin I) than other tissues and hemolysis is almost always present in persons with CEP. Whether it is accompanied by anemia depends on whether erythroid hyperplasia is sufficient to compensate for the increased rate of erythrocyte destruction, which may vary over time. More severely affected individuals are transfusion dependent.</p><p>Splenomegaly usually develops secondary to hemolysis and can also lead to thrombocytopenia and leukopenia. In addition, porphyrin deposition also occurs in the spleen and to a lesser degree in the liver.</p><p>
|
|
<b>Mechanism of disease causation</b>
|
|
</p><ul><li class="half_rhythm"><div><i>UROS</i> pathogenic variants result in either absent or reduced UROS enzymatic activity.</div></li><li class="half_rhythm"><div><i>GATA1</i> pathogenic variants alter the binding of GATA1 to URO-synthase, resulting in significantly reduced (~20% of normal) URO-synthase activity [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>].</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepTcongenitalerythropoieticporphyri"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figobcepTcongenitalerythropoieticporphyri"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.T.congenital_erythropoietic_porphyri"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri">Table 4. </a></h4><p class="float-caption no_bottom_margin">Congenital Erythropoietic Porphyria: Gene-Specific Laboratory Considerations </p></div></div><p><b>Disease modifiers.</b> The CEP phenotype may be modulated by sequence variants in <i>ALAS2</i>, mutation of which typically causes <a href="/books/n/gene/epp-xl/?report=reader">X-linked protoporphyria</a> (XLP)<i>.</i> A novel c.1757A>T (p.Tyr586Phe) variant in exon 11 of <i>ALAS2</i> was identified in a girl with severe CEP who had biallelic <i>UROS</i> pathogenic variants [<a class="bibr" href="#cep.REF.tofigueras.2011.1443" rid="cep.REF.tofigueras.2011.1443">To-Figueras et al 2011</a>].</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcepTcongenitalerythropoieticporphyri1"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figobcepTcongenitalerythropoieticporphyri1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cep.T.congenital_erythropoietic_porphyri_1"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">Table 5. </a></h4><p class="float-caption no_bottom_margin">Congenital Erythropoietic Porphyria: Notable Pathogenic Variants by Gene </p></div></div></div></div><div id="cep.Chapter_Notes"><h2 id="_cep_Chapter_Notes_">Chapter Notes</h2><div id="cep.Acknowledgments"><h3>Acknowledgments</h3><p>The <i>GeneReview</i> "Congenital Erythropoietic Porphyria" was supported in part by the Porphyrias Consortium of the NIH-supported <a href="https://www.rarediseasesnetwork.org/cms/porphyrias" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Rare Diseases Clinical Research Network</a> (NIH grant: 5 U54 DK083909).</p></div><div id="cep.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 April 2021 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 April 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 September 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>5 March 2013 (ae) Original submission</div></li></ul></div></div><div id="cep.References"><h2 id="_cep_References_">References</h2><div id="cep.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.anderson.2001">Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, eds. <em>The Metabolic and Molecular Basis of Inherited Disease.</em> 8 ed. New York, NY: McGraw-Hill; 2001:2991.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.bickers.1987.261">Bickers DR. The dermatologic manifestations of human porphyria. <span><span class="ref-journal">Ann N Y Acad Sci. </span>1987;<span class="ref-vol">514</span>:261–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3327430" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3327430</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.bishop.2006.645">Bishop DF, Johansson A, Phelps R, Shady AA, Ramirez MC, Yasuda M, Caro A, Desnick RJ. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">78</span>:645–58.</span> [<a href="/pmc/articles/PMC1424695/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1424695</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16532394" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16532394</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.blouin.2021.100722">Blouin JM, Ged C, Bernardo-Seisdedos G, Cabantous T, Pinson B, Poli A, Puy H, Millet O, Gouya L, Morice-Picard F, Richard E. Identification of novel UROS mutations in a patient with congenital erythropoietic porphyria and efficient treatment by phlebotomy. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2021;<span class="ref-vol">27</span>:100722. </span> [<a href="/pmc/articles/PMC7890299/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7890299</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33659185" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33659185</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.blouin.2020.2457">Blouin JM, Ged C, Lalanne M, Lamrissi-Garcia I, Morice-Picard F, Costet P, Daher R, Moreau-Gaudry F, Bedel A, Puy H, Gouya L, Karim Z, Richard E. Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. <span><span class="ref-journal">Blood. </span>2020;<span class="ref-vol">136</span>:2457–68.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32678895" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32678895</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.boulechfar.1992.320">Boulechfar S, Da Silva V, Deybach JC, Nordmann Y, Grandchamp B, de Verneuil H. Heterogeneity of mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. <span><span class="ref-journal">Hum Genet. </span>1992;<span class="ref-vol">88</span>:320–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1733834" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1733834</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.da_khadahmane.2001.180">Daïkha-Dahmane F, Dommergues M, Narcy F, Gubler MC, Dumez Y, Gauthier E, Nordmann Y, Nessmann C, Terrasse G, Muller F. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. <span><span class="ref-journal">Pediatr Dev Pathol. </span>2001;<span class="ref-vol">4</span>:180–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11178635" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11178635</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.dawe.2002.680">Dawe SA, Peters TJ, Du Vivier A, Creamer JD. Congenital erythropoietic porphyria: dilemmas in present day management. <span><span class="ref-journal">Clin Exp Dermatol. </span>2002;<span class="ref-vol">27</span>:680–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12472546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12472546</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.desnick.2002.779">Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:779–95.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12060112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12060112</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.desnick.1998.77">Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH. Molecular genetics of congenital erythropoietic porphyria. <span><span class="ref-journal">Semin Liver Dis. </span>1998;<span class="ref-vol">18</span>:77–84.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9516681" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9516681</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.di_pierro.2015.491">Di Pierro E, Russo R, Karakas Z, Brancaleoni V, Gambale A, Kurt I, Winter SS, Granata F, Czuchlewski DR, Langella C, Iolascon A, Cappellini MD. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis. <span><span class="ref-journal">Eur J Haematol. </span>2015;<span class="ref-vol">94</span>:491–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25251786" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25251786</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.dupuisgirod.2005.104">Dupuis-Girod S, Akkari V, Ged C, Galambrun C, Kebaïli K, Deybach JC, Claudy A, Geburher L, Philippe N, de Verneuil H, Bertrand Y. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease). <span><span class="ref-journal">Eur J Pediatr. </span>2005;<span class="ref-vol">164</span>:104–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15703981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15703981</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.egan.2015.257">Egan DN, Yang Z, Phillips J, Abkowitz JL. Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>:257–61.</span> [<a href="/pmc/articles/PMC4497965/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4497965</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25972160" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25972160</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.faraci.2008.117">Faraci M, Morreale G, Boeri E, Lanino E, Dallorso S, Dini G, Scuderi F, Cohen A, Cappelli B. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. <span><span class="ref-journal">Pediatr Transplant. </span>2008;<span class="ref-vol">12</span>:117–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18186900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18186900</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.frank.1998.225">Frank J, Wang X, Lam HM, Aita VM, Jugert FK, Goerz G, Merk HF, Poh-Fitzpatrick MB, Christiano AM. C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. <span><span class="ref-journal">Ann Hum Genet. </span>1998;<span class="ref-vol">62</span>:225–30.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9803266" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9803266</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.fritsch.1997.594">Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. <span><span class="ref-journal">J Am Acad Dermatol. </span>1997;<span class="ref-vol">36</span>:594–610.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9092747" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9092747</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.ged.2004.589">Ged C, Mégarbané H, Chouery E, Lalanne M, Mégarbané A, de Verneuil H. Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. <span><span class="ref-journal">J Invest Dermatol. </span>2004;<span class="ref-vol">123</span>:589–91.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15304101" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15304101</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.hallai.2007.622">Hallai N, Anstey A, Mendelsohn S, Williams J, Evans-Jones G, Malick S, Badminton MN. Pregnancy in a patient with congenital erythropoietic porphyria. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:622–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17687144" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17687144</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.harada.2001.279">Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. <span><span class="ref-journal">J Am Acad Dermatol. </span>2001;<span class="ref-vol">45</span>:279–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11464191" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11464191</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.katugampola.2012a.888">Katugampola RP, Anstey AV, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Badminton MN. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. <span><span class="ref-journal">Br J Dermatol. </span>2012a;<span class="ref-vol">167</span>:888–900.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22804244" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22804244</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.katugampola.2012b.901">Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Anstey AV. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. <span><span class="ref-journal">Br J Dermatol. </span>2012b;<span class="ref-vol">167</span>:901–13.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22816431" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22816431</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.kaufman.1967.210">Kaufman BM, Vickers HR, Rayne J, Ryan TJ. Congenital erythropoietic porphyria. Report of a case. <span><span class="ref-journal">Br J Dermatol. </span>1967;<span class="ref-vol">79</span>:210–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6024737" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6024737</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.kontos.2003.160">Kontos AP, Ozog D, Bichakjian C, Lim HW. Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature. <span><span class="ref-journal">Br J Dermatol. </span>2003;<span class="ref-vol">148</span>:160–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12534613" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12534613</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.laorr.1994.307">Laorr A, Greenspan A. Severe osteopenia in congenital erythropoietic porphyria. <span><span class="ref-journal">Can Assoc Radiol J. </span>1994;<span class="ref-vol">45</span>:307–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8062123" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8062123</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.mirmiran.2021.913">Mirmiran A, Poli A, Ged C, Schmitt C, Lefebvre T, Manceau H, Daher R, Moulouel B, Peoc'h K, Simonin S, Blouin JM, Deybach JC, Nicolas G, Puy H, Richard E, Gouya L. Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. <span><span class="ref-journal">Haematologica. </span>2021;<span class="ref-vol">106</span>:913–7.</span> [<a href="/pmc/articles/PMC7927993/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7927993</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31919078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31919078</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.oguz.1993.671">Oguz F, Sidal M, Bayram C, Sansoy N, Hekim N. Ocular involvement in two symptomatic congenital erythropoietic porphyria. <span><span class="ref-journal">Eur J Pediatr. </span>1993;<span class="ref-vol">152</span>:671–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8404971" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8404971</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.pain.1975.621">Pain RW, Welch FW, Woodroffe AJ, Handley DA, Lockwood WH. Erythropoietic uroporphyria of Gunther first presenting at 58 years with positive family studies. <span><span class="ref-journal">Br Med J. </span>1975;<span class="ref-vol">3</span>:621–3.</span> [<a href="/pmc/articles/PMC1674443/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1674443</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1164638" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1164638</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.phillips.2007.2618">Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:2618–21.</span> [<a href="/pmc/articles/PMC1852202/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1852202</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17148589" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17148589</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.piomelli.1986.1029">Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">314</span>:1029–31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3960070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3960070</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick MB, Piomelli S, Seaman C, Skolnick LM. Congenital erythropoietic porphyria: complete suppression of symptoms by long-term high-level transfusion with deferoxamine infusion iron rescue. In: Orfanos CE, Stadler R, Gollnick H, eds. <em>Dermatology in Five Continents</em>. Berlin, Germany: Springer Verlag; 1988:876-9.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.pohfitzpatrick.1985">Poh-Fitzpatrick MB. Porphyrin sensitized cutaneous photosensitivity - pathogenesis and treatment. In: Disler PB, Moore MR, eds. <em>Porphyria-Clinics in Dermatology</em>. Philadelphia, PA: Lippincott; 1985:41-82. [<a href="https://pubmed.ncbi.nlm.nih.gov/3916834" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3916834</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick MB. The erythropoietic porphyrias. <span><span class="ref-journal">Dermatol Clin. </span>1986;<span class="ref-vol">4</span>:291–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3955899" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3955899</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.sarkany.2011.1172">Sarkany RP, Ibbotson SH, Whatley SD, Lawrence CM, Gover P, Mufti GJ, Murphy GM, Masters GS, Badminton MN, Elder GH. Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyria. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:1172–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21326293" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21326293</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.schmid.1955.416">Schmid R, Schwartz S, Sundberg RD. Erythropoietic (congenital) porphyria: a rare abnormality of the normoblasts. <span><span class="ref-journal">Blood. </span>1955;<span class="ref-vol">10</span>:416–28.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14363322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14363322</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.shady.2002.980">Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:980–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12060141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12060141</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.shaw.2001.101">Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. <span><span class="ref-journal">Bone Marrow Transplant. </span>2001;<span class="ref-vol">27</span>:101–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11244446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11244446</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.siddique.2011.97">Siddique SS, Gonzalez-Gonzalez LA, Thakuria P, Chang PY, Foster CS. Scleral necrosis in a patient with congenital erythropoietic porphyria. <span><span class="ref-journal">Cornea. </span>2011;<span class="ref-vol">30</span>:97–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20847674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20847674</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.solis.2001.753">Solis C, Aizencang GI, Astrin KH, Bishop DF, Desnick RJ. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. <span><span class="ref-journal">J Clin Invest. </span>2001 Mar;<span class="ref-vol">107</span>:753–62.</span> [<a href="/pmc/articles/PMC208941/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC208941</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11254675" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11254675</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.stenson.2020.1197">Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. <span><span class="ref-journal">Hum Genet. </span>2020;<span class="ref-vol">139</span>:1197–207.</span> [<a href="/pmc/articles/PMC7497289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7497289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32596782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32596782</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.taibjee.2007.567">Taibjee SM, Stevenson OE, Abdullah A, Tan CY, Darbyshire P, Moss C, Goodyear H, Heagerty A, Whatley S, Badminton MN. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. <span><span class="ref-journal">Br J Dermatol. </span>2007;<span class="ref-vol">156</span>:567–71.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17300251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17300251</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.tezcan.1998.4053">Tezcan I, Xu W, Gurgey A, Tuncer M, Cetin M, Oner C, Yetgin S, Ersoy F, Aizencang G, Astrin KH, Desnick RJ. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. <span><span class="ref-journal">Blood. </span>1998;<span class="ref-vol">92</span>:4053–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9834209" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9834209</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.thomas.1996.453">Thomas C, Ged C, Nordmann Y, de Verneuil H, Pellier I, Fischer A, Blanche S. Correction of congenital erythropoietic porphyria by bone marrow transplantation. <span><span class="ref-journal">J Pediatr. </span>1996;<span class="ref-vol">129</span>:453–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8804339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8804339</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.tishler.1990.645">Tishler PV, Winston SH. Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal. <span><span class="ref-journal">Methods Find Exp Clin Pharmacol. </span>1990;<span class="ref-vol">12</span>:645–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2084460" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2084460</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.tofigueras.2011.1443">To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, Lyoumi S, Gouya L, de Verneuil H, Beaumont C, Ferreira GC, Deybach JC, Herrero C, Puy H. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:1443–51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21653323" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21653323</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.urquiza.2018.eaat7467">Urquiza P, Lain A, Sanz-Parra A, Moreno J, Bernardo-Seisdedos G, Dubus P, González E, Gutiérrez-de-Juan V, García S, Eraña H, San Juan I, Macías I, Ben Bdira F, Pluta P, Ortega G, Oyarzábal J, González-Muñiz R, Rodríguez-Cuesta J, Anguita J, Díez E, Blouin JM, de Verneuil H, Mato JM, Richard E, Falcón-Pérez JM, Castilla J, Millet O. Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. <span><span class="ref-journal">Sci Transl Med. </span>2018;<span class="ref-vol">10</span>:eaat7467. </span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30232228" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30232228</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.venkatesh.2000.314">Venkatesh P, Garg SP, Kumaran E, Tewari HK. Congenital porphyria with necrotizing scleritis in a 9-year-old child. <span><span class="ref-journal">Clin Experiment Ophthalmol. </span>2000;<span class="ref-vol">28</span>:314–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11021563" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11021563</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.wahlin.2008.1340">Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. <span><span class="ref-journal">Liver Transpl. </span>2008;<span class="ref-vol">14</span>:1340–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18756472" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18756472</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.warner.1992.693">Warner CA, Yoo HW, Roberts AG, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene. <span><span class="ref-journal">J Clin Invest. </span>1992;<span class="ref-vol">89</span>:693–700.</span> [<a href="/pmc/articles/PMC442904/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC442904</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1737856" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1737856</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.weston.1978.921">Weston MJ, Nicholson DC, Lim CK, Clark KG, Macdonald A, Henderson MA, Williams R. Congenital erythropoietic uroporphyria (Günther's disease) presenting in a middle aged man. <span><span class="ref-journal">Int J Biochem. </span>1978;<span class="ref-vol">9</span>:921–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/744297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 744297</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cep.REF.zixkieffer.1996.217">Zix-Kieffer I, Langer B, Eyer D, Acar G, Racadot E, Schlaeder G, Oberlin F, Lutz P. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). <span><span class="ref-journal">Bone Marrow Transplant. </span>1996;<span class="ref-vol">18</span>:217–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8832020" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8832020</span></a>]</div></p></li></ul></div></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>*</dt><dd><div id="cep.Tb.an4"><p class="no_top_margin">See Chapter Notes, <a href="#cep.Acknowledgments">Acknowledgments</a>.</p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK154652_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Angelika Erwin</span>, MD, PhD<div class="affiliation small">Cleveland Clinic
|
|
Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@aniwre" class="oemail">gro.fcc@aniwre</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Manisha Balwani</span>, MD, MS<div class="affiliation small">Icahn School of Medicine at Mount Sinai
|
|
New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@inawlab.ahsinam" class="oemail">ude.mssm@inawlab.ahsinam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert J Desnick</span>, MD, PhD, FACMG<div class="affiliation small">Icahn School of Medicine at Mount Sinai
|
|
New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@kcinsed.trebor" class="oemail">ude.mssm@kcinsed.trebor</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span><sup><a href="#cep.Tb.an4">*</a></sup></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">September 12, 2013</span>; Last Update: <span itemprop="dateModified">April 15, 2021</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>Erwin A, Balwani M, Desnick RJ; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Congenital Erythropoietic Porphyria. 2013 Sep 12 [Updated 2021 Apr 15]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/cda1/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/cftd/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobcepTbiochemicalcharacteristicsofcon"><div id="cep.T.biochemical_characteristics_of_con" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of Congenital Erythropoietic Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.biochemical_characteristics_of_con_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Defect</th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity <sup>1</sup></th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tissue</th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uroporphyrin <sup>1</sup></th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coproporphyrin <sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Uroporphyrinogen III synthase (URO-synthase) <sup>2</sup></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Undetectable to ~10% of normal mean activity in erythrocytes</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Urine</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Stool</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Amniotic fluid <sup>3</sup></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↑</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">↑ = markedly elevated</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cep.TF.1.1"><p class="no_margin">The deficient activity of uroporphyrinogen III synthase EC 4.2.1.75, encoded by <i>UROS</i>, results in non-enzymatic conversion of hydroxymethylbilane to uroporphyrinogen I, which is then metabolized to coproporphyrinogen I. Coproporphyrinogen I cannot be metabolized further. These metabolites are then oxidized to uroporphyrin I and coproporphyrin I, respectively, which are non-physiologic and pathogenic.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cep.TF.1.2"><p class="no_margin">The assay for the enzyme uroporphyrinogen III synthase is available on a clinical basis and can be used to establish the diagnosis of congenital erythropoietic porphyria.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cep.TF.1.3"><p class="no_margin">Amniotic fluid appears red to dark brown. Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells [<a class="bibr" href="#cep.REF.da_khadahmane.2001.180" rid="cep.REF.da_khadahmane.2001.180">Daïkha-Dahmane et al 2001</a>].</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcepTmoleculargenetictestingusedin"><div id="cep.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Congenital Erythropoietic Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of CEP Attributed to Pathogenic Variants in Gene</th><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants <sup>2</sup> Detected by Method</th></tr><tr><th headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis <sup>3</sup></th><th headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted deletion/duplication analysis <sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UROS</i>
|
|
</td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>98% <sup>5</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90% <sup>5</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10% <sup>6</sup></td></tr><tr><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>GATA1</i>
|
|
</td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1% <sup>7</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CEP = congenital erythropoietic porphyria</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cep.TF.2.1"><p class="no_margin">See <a href="/books/NBK154652/?report=reader#cep.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cep.TF.2.2"><p class="no_margin">See <a href="#cep.Molecular_Genetics">Molecular Genetics</a> for information on variants detected in these genes.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cep.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/?report=reader">here</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="cep.TF.2.4"><p class="no_margin">Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="cep.TF.2.5"><p class="no_margin">Data derived from the subscription-based professional view of Human Gene Mutation Database [<a class="bibr" href="#cep.REF.stenson.2020.1197" rid="cep.REF.stenson.2020.1197">Stenson et al 2020</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="cep.TF.2.6"><p class="no_margin">Two gross deletions, two gross duplications, and one complex rearrangement have been reported [<a class="bibr" href="#cep.REF.boulechfar.1992.320" rid="cep.REF.boulechfar.1992.320">Boulechfar et al 1992</a>, <a class="bibr" href="#cep.REF.shady.2002.980" rid="cep.REF.shady.2002.980">Shady et al 2002</a>, <a class="bibr" href="#cep.REF.katugampola.2012a.888" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="cep.TF.2.7"><p class="no_margin">A <i>GATA1</i> pathogenic variant (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.646C>T</a> [p.Arg216Trp]) was identified in three unrelated individuals with CEP and hematologic abnormalities [<a class="bibr" href="#cep.REF.phillips.2007.2618" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bibr" href="#cep.REF.di_pierro.2015.491" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcepTdisorderstoconsiderinthediffe"><div id="cep.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Congenital Erythropoietic Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features</th></tr><tr><th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping</th><th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing</th></tr></thead><tbody><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Porphyria cutanea tarda (PCT) type I (OMIM <a href="https://omim.org/entry/176090" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">176090</a>)</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">See footnote 1.</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cutaneous photosensitivity w/blistering & friability of skin in sun-exposed areas</div></li><li class="half_rhythm"><div>Facial hypertrichosis</div></li><li class="half_rhythm"><div>Discolored urine</div></li></ul>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Usually manifests in adulthood</div></li><li class="half_rhythm"><div>Distinct biochemical porphyrin profile</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/porphyria-ct/?report=reader">Porphyria cutanea tarda (PCT) type II</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UROD</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/hep/?report=reader">Hepato-erythropoietic porphyria</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UROD</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Phenotype similar to PCT</div></li><li class="half_rhythm"><div>Manifests in early childhood</div></li><li class="half_rhythm"><div>Discolored urine</div></li><li class="half_rhythm"><div>Photosensitivity</div></li></ul>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Distinct biochemical porphyrin profile</div></li><li class="half_rhythm"><div>Developmental delay (in some)</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/hcp/?report=reader">Hereditary coproporphyria</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CPOX</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">20% of affected persons experience photosensitivity w/skin blistering in sun-exposed areas.</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Acute (hepatic) porphyria</div></li><li class="half_rhythm"><div>Acute attacks of abdominal or generalized pain; can be assoc w/neurologic symptoms</div></li><li class="half_rhythm"><div>Incompletely penetrant in absence of environmental inducers</div></li><li class="half_rhythm"><div>Usually manifests after puberty</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/porphyria-var/?report=reader">Variegate porphyria</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>PPOX</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myeloid malignancy</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elderly adults w/myelodysplastic syndrome may exhibit features of CEP. <sup>2, 3</sup></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/ebs/?report=reader">Epidermolysis bullosa simplex (EBS)</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>KRT5</i>
|
|
<br />
|
|
<i>KRT14</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD <sup>4</sup></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fragility of skin → nonscarring blisters caused by little/no trauma</div></li><li class="half_rhythm"><div>Major & minor subtypes share common feature of blistering above dermal-epidermal junction at the ultrastructural level.</div></li></ul>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/ebj/?report=reader">Junctional epidermolysis bullosa (JEB)</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>LAMA3</i>
|
|
<br />
|
|
<i>LAMB3</i>
|
|
<br />
|
|
<i>LAMC2</i>
|
|
<br />
|
|
<i>COL17A1</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fragility of skin & mucous membranes, manifest by blistering w/little or no trauma</div></li><li class="half_rhythm"><div>Herlitz JEB (classic severe form): blisters present at birth or become apparent in neonatal period</div></li><li class="half_rhythm"><div>Non-Herlitz JEB: may be mild w/blistering localized to hands, feet, knees, elbows</div></li></ul>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/ebd/?report=reader">Dystrophic epidermolysis bullosa</a>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>COL7A1</i>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blisters affecting whole body may be present in neonatal period.</div></li><li class="half_rhythm"><div>Oral involvement</div></li><li class="half_rhythm"><div>Corneal erosions</div></li></ul>
|
|
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Esophageal erosions</div></li><li class="half_rhythm"><div>Severe nutritional deficiency & secondary problems</div></li><li class="half_rhythm"><div>"Mitten" hands & feet</div></li><li class="half_rhythm"><div>>90% lifetime risk of aggressive squamous cell carcinoma</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blistering, often mild & limited to hands, feet, knees, elbows; heals w/scarring</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic nails possibly the only manifestation</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; AR = autosomal recessive; MOI = mode of inheritance</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cep.TF.3.1"><p class="no_margin">80% of persons with porphyria cutanea tarda (PCT) have type I PCT (also referred to as acquired or "sporadic" PCT because it is not known to be associated with an inherited genetic alteration). Type I PCT is characterized by normal URO-decarboxylase activity systemically when affected individuals are asymptomatic. Inhibition of the enzyme activity resulting in PCT can be caused by excessive alcohol intake, hemochromatosis, viral hepatitis (mostly hepatitis C), HIV infection, certain medications, and environmental exposures such as aromatic polyhalogenated hepatotoxins. Treatment consists of eliminating or treating the underlying cause and, if symptoms persist, frequent phlebotomies or therapy with oral low-dose hydroxychloroquine.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cep.TF.3.2"><p class="no_margin"><a class="bibr" href="#cep.REF.fritsch.1997.594" rid="cep.REF.fritsch.1997.594">Fritsch et al [1997]</a>, <a class="bibr" href="#cep.REF.kontos.2003.160" rid="cep.REF.kontos.2003.160">Kontos et al [2003]</a>, <a class="bibr" href="#cep.REF.sarkany.2011.1172" rid="cep.REF.sarkany.2011.1172">Sarkany et al [2011]</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cep.TF.3.3"><p class="no_margin">Affected individuals had normal erythrocyte URO-synthase activity. Presumably, the CEP-like manifestations resulted from genetic or functional changes associated with the bone marrow disorder.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="cep.TF.3.4"><p class="no_margin">EBS caused by pathogenic variants in <i>KRT5</i> or <i>KRT14</i> is usually inherited in an autosomal dominant manner; in rare families, especially those with consanguinity, it can be inherited in an autosomal recessive manner.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcepmolgenTA"><div id="cep.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Congenital Erythropoietic Porphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2623" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>GATA1</i>
|
|
</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2623" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Xp11<wbr style="display:inline-block"></wbr>​.23</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/P15976" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Erythroid transcription factor</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/GATA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">GATA1 @ LOVD</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GATA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">GATA1</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GATA1[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">GATA1</a>
|
|
</td></tr><tr><td headers="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/7390" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>UROS</i>
|
|
</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=7390" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">10q26<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/P10746" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Uroporphyrinogen-III synthase</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://databases.lovd.nl/shared/genes/UROS" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UROS database</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UROS" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UROS</a>
|
|
</td><td headers="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UROS[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UROS</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div id="cep.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
|
|
<a href="http://www.genenames.org/index.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">HGNC</a>;
|
|
chromosome locus from
|
|
<a href="http://www.omim.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">OMIM</a>;
|
|
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UniProt</a>.
|
|
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
|
|
<a href="/books/n/gene/app1/?report=reader">here</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcepmolgenTB"><div id="cep.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Congenital Erythropoietic Porphyria (<a href="/omim/263700,305371,606938" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/263700" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">263700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/305371" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">305371</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GATA-BINDING PROTEIN 1; GATA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/606938" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">606938</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UROPORPHYRINOGEN III SYNTHASE; UROS</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobcepTcongenitalerythropoieticporphyri"><div id="cep.T.congenital_erythropoietic_porphyri" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Congenital Erythropoietic Porphyria: Gene-Specific Laboratory Considerations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.congenital_erythropoietic_porphyri_lrgtbl__"><table><thead><tr><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Special Consideration</th></tr></thead><tbody><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UROS</i>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regulatory pathogenic variants, located in the erythroid-specific promoter region (intron 1 upstream of the exon 2 ATG), can be detected by sequence analysis when this DNA region is included in the analysis. See <a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">Table 5</a>.</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>GATA1</i>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To date, only one <i>GATA1</i> variant (<a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object" rid-ob="figobcepTcongenitalerythropoieticporphyri1">c.646C>T [p.Arg216Trp]</a>) has been described as causative of CEP.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobcepTcongenitalerythropoieticporphyri1"><div id="cep.T.congenital_erythropoietic_porphyri_1" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Congenital Erythropoietic Porphyria: Notable Pathogenic Variants by Gene</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.congenital_erythropoietic_porphyri_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.congenital_erythropoietic_porphyri_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change (Alias <sup>1</sup>)</th><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_1" rowspan="10" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UROS</i>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_2" rowspan="10" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000375.2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000375<wbr style="display:inline-block"></wbr>​.2</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/NP_000366.1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_000366<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.139T>C</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser47Pro</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assoc w/a severe CEP phenotype; however, in 1 family w/5 children homozygous for this variant, 4 children had severe clinical findings while 1 had very mild cutaneous findings [<a class="bibr" href="#cep.REF.ged.2004.589" rid="cep.REF.ged.2004.589">Ged et al 2004</a>].</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.197C>T</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala66Val</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.217T>C</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys73Arg</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most common <i>UROS</i> pathogenic variant observed in ~1/3 of affected persons <sup>2</sup></td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.244G>T</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val82Phe</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.311C>T</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala104Val</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.673G>A</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly225Ser</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-203T>C<br />(-70T>C)</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic variants in the erythroid-specific promoter region <sup>2</sup></td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-209G>A<br />(-76G>A)</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-219C>A<br />(-86C>A)</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.-223C>A<br />(-90C>A)</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>GATA1</i>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002049.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_002049<wbr style="display:inline-block"></wbr>​.3</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/NP_002040.1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_002040<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.646C>T</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg216Trp</td><td headers="hd_h_cep.T.congenital_erythropoietic_porphyri_1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="https://varnomen.hgvs.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/?report=reader">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cep.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cep.TF.5.2"><p class="no_margin">See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|